Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label mass balance study of radiolabeled EYP001a in healthy men
NL-OMON48170Completed
- Sponsor
- ENYO Pharma
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of vonafexor in Chronic Hepatitis B (CHB) and metabolic dysfunction-associated steatohepatitis (MASH), sponsored by ENYO Pharma. Primary endpoints: Radioactivity-time profile in whole blood, Radioactivity-time profile in plasma and 1 more. Started Jul 2019; status: completed.
02
Drugs
vonafexor
03
Conditions
Chronic Hepatitis B (CHB)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON48170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48170.